ResMed Inc.— Sankey Diagram
Annual mode · period ending 2025-12-31 · SEC EDGAR
FY2025 - Q4(Oct 25 · Nov 25 · Dec 25)
Total Assets
$8.50B
↑+19.1% +$1.36Bvs FY2024
Total Liabilities
$2.18B
↑+15.6% +$294Mvs FY2024
Equity
$6.32B
↑+20.3% +$1.07Bvs FY2024
Cash
$1.42B
↑+171.5% +$895Mvs FY2024
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 | FY2024 |
|---|---|---|
| Total Assets | $8.50B | $7.14B |
| Current Assets | $3.82B | $2.84B |
| Cash | $1.42B | $522M |
| ST Investments | $0 | $0 |
| Receivables | $986M | $860M |
| Inventory | $922M | $882M |
| Other Current | $494M | $572M |
| Non-Current Assets | $4.68B | $4.31B |
| PPE | $564M | $520M |
| Goodwill | $3.04B | $2.81B |
| Intangibles | $430M | $438M |
| Investments | $0 | $0 |
| Other Non-Current | $646M | $542M |
| Total Liab+Eq | $8.50B | $7.14B |
| Current Liab. | $1.25B | $852M |
| Accounts Payable | $250M | $220M |
| Short-Term Debt | $260M | $10M |
| Deferred Revenue | $176M | $157M |
| Other CL | $562M | $465M |
| Non-Current Liab. | $934M | $1.04B |
| Long-Term Debt | $404M | $663M |
| Other LT Liab. | $530M | $374M |
| Equity | $6.32B | $5.25B |
| Retained Earnings | $6.65B | $5.49B |
| Other Equity | $0 | $0 |
QuarterCharts · SEC EDGAR data · RMD · Comparing FY2025 vs FY2024